Sanjeev Kumar Sharma*, Dharma Choudhary, Meet Kumar, Vipin Khandelwal, Divya Doval, Anil Handoo, Rasika Setia, and Tina Dadu
Department of Hemato-oncology and Bone Marrow Transplantation, BLK Superspeciality Hospital, India
Corresponding Author:
Sanjeev Kumar Sharma, Senior Consultant and Principal Coordinator,Department of Hemato-oncology and Bone Marrow Transplantation, BLK Superspeciality Hospital, New Delhi-110005, India, Email: sksanjeev13@yahoo.com
Keywords:
Abstract
Autologous Stem Cell Transplantation (ASCT) is the preferred treatment for the management of multiple myeloma after initial 4-6 months of induction treatment.
Citation
Sharma SK, Choudhary D, Kumar M, Khandelwal V, Doval D, Handoo A, et al. Stem Cell Transplant for Multiple Myeloma: A Single Center Experience from Northern India. SM J Hematol Oncol. 2018; 3(1): 1010s.
